Recent diagnostic and therapeutic innovations in heart failure management.
Although there has been substantial progress in the treatment of congestive heart failure over the last several decades, it is clear that heart failure continues to burden our aging population. As the epidemic of heart failure grows, there remains an unmistakable need for novel diagnostic and therapeutic options in its management. In this article, we review recent innovations in the management of congestive heart failure, highlighting several recent clinical trials.
Gehi
Anil K
AK
Box 1030, Mount Sinai School of Medicine, One East 100th Street, New York, NY 10029. anil.gehi@msyuhealth.org
Pinney
Sean P
SP
Gass
Alan
A
D000367:Age Factors; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein; D002317:Cardiovascular Agents / Q000145:classification / Q000627:therapeutic use; D006333:Heart Failure / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000145:classification / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D013841:Thiazepines / Q000627:therapeutic use
D015415:Biomarkers; D002317:Cardiovascular Agents; D018377:Neurotransmitter Agents; D011725:Pyridines; D013841:Thiazepines; D020097:Natriuretic Peptide, Brain; C106266:omapatrilat; D002097:C-Reactive Protein